Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

Documenti analoghi

• Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
  di: Hill, Andrew, et al.
  Pubblicazione: (2014)
• Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
  di: Hill, Andrew, et al.
  Pubblicazione: (2016)
• Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
  di: Hill, Andrew, et al.
  Pubblicazione: (2015)
• Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis
  di: Jones, Christopher R., et al.
  Pubblicazione: (2019)
• Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
  di: Simmons, Bryony, et al.
  Pubblicazione: (2014)